CUE · Cue Biopharma, Inc. · Executive Compensation
$25.57
+0.32 (+1.27%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 14, 2026Market Cap
$194.11M
Shares
7.26M
Volume · Oct 2
156.86K
Avg daily vol (3M)
262.97K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel Passeri | Former Chief Executive Officer | $1,426,183 |
| Daniel R. Passeri | Former Chief Executive Officer | $1,426,183 |
| Matteo Levisetti | Former Chief Medical Officer | $1,219,364 |
| Usman Azam | President and Chief Executive Officer | $1,185,639 |
| Lucinda Warren | Chief Financial and Business Officer | $801,223 |
| Colin G. Sandercock | SVP, General Counsel and Secretary | $599,222 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel Passeri | Former Chief Executive Officer | $1,393,921 |
| Daniel R. Passeri | Former Chief Executive Officer | $1,393,921 |
| Matteo Levisetti | Former Chief Medical Officer | $1,191,276 |
| Anish Suri | Former President and Chief Scientific Officer | $1,180,114 |
| Kerri-Ann Millar | Chief Financial Officer | $1,044,784 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Daniel Passeri | Chief Executive Officer | $3,015,480 |
| Daniel R. Passeri | Chief Executive Officer | $3,015,480 |
| Anish Suri | Former President and Chief Scientific Officer | $1,242,468 |
| Kerri-Ann Millar | Chief Financial Officer | $1,162,538 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Daniel R. Passeri | Chief Executive Officer | $1,373,850 |
| Daniel Passeri | Chief Executive Officer | $1,373,850 |
| Anish Suri | President and Chief Scientific Officer | $1,167,654 |
| Kerri-Ann Millar | Chief Financial Officer | $1,056,925 |
| Kerri Millar | Chief Financial Officer | $1,056,924 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Daniel R. Passeri | Chief Executive Officer | $1,820,756 |
| Daniel Passeri | Chief Executive Officer | $1,820,756 |
| Anish Suri | President and Chief Scientific Officer | $1,521,227 |
| Kerri Millar | Chief Financial Officer | $1,358,011 |
| Kerri-Ann Millar | Chief Financial Officer | $1,358,011 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Daniel Passeri | Chief Executive Officer | $5,841,786 |
| Daniel R. Passeri | Chief Executive Officer | $5,841,786 |
| Kerri-Ann Millar | Chief Financial Officer | $2,194,633 |
| Anish Suri | President and Chief Scientific Officer | $2,128,670 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Anish Suri | President and Chief Scientific Officer | $4,559,814 |
| Daniel Passeri | Chief Executive Officer | $1,198,614 |
| Daniel R. Passeri | Chief Executive Officer | $1,198,614 |
| Colin G. Sandercock | Senior Vice President, General Counsel and Secretary | $625,514 |
| Kerri-Ann Millar | Chief Financial Officer | $448,321 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Anish Suri | President and Chief Scientific Officer | $3,221,156 |
| Daniel Passeri | Chief Executive Officer | $833,858 |
| Daniel R. Passeri | Chief Executive Officer | $833,858 |
| Colin G. Sandercock | Senior Vice President, General Counsel and Secretary | $330,220 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James Ahlers | Chief Financial Officer | Appointed | 2026-08-03 |
| Viola Meehan | director | Appointed | 2026-06-02 |
| Michael Meluzio | Vice President, Principal Accounting Officer | Appointed | 2026-06-02 |
| Daniel Camardo | director | Appointed | 2026-06-02 |
| Sumita Ray | Chief Legal & Compliance Officer and Corporate Secretary | Appointed | 2026-06-02 |
| Patrick Verheyen | member of the Board of Directors | Resigned | 2026-06-02 |
| Frank Morich | member of the Board of Directors | Resigned | 2026-06-02 |
| Peter Kiener | member of the Board of Directors | Resigned | 2026-06-02 |
| Jill Broadfoot | member of the Board of Directors | Resigned | 2026-06-02 |
| Lucinda Warren | Interim President and Chief Executive Officer | Resigned | 2026-05-01 |
| Dr. Shao-Lee Lin | member of the Board | Appointed | 2026-05-01 |
| Dr. Shao-Lee Lin | President and Chief Executive Officer | Appointed | 2026-05-01 |
| Usman Azam | member of the Board | Resigned | 2026-03-27 |
| Usman Azam | President and Chief Executive Officer | Resigned | 2026-03-27 |
| Lucinda Warren | Interim President and Chief Executive Officer | Appointed | 2026-03-27 |
| Lucinda Warren | Chief Financial and Business Officer | Appointed | 2026-02-12 |
| Matteo Levisetti | Chief Medical Officer | Terminated | 2025-11-20 |
| Daniel R. Passeri | member of the Board | Resigned | 2025-09-29 |
| Usman Azam | member of the Board | Appointed | 2025-09-29 |
| Daniel R. Passeri | Chief Executive Officer | Retired | 2025-09-29 |
| Usman Azam | President and Chief Executive Officer | Appointed | 2025-09-29 |
| Daniel R. Passeri | principal financial and accounting officer on an interim basis | Appointed | 2025-06-10 |
| Kerri-Ann Millar | Chief Financial Officer | Resigned | 2025-06-10 |
| Jill Broadfoot | member of the board of directors | Appointed | 2025-06-10 |
| Pasha Sarraf | board of directors | Appointed | 2025-03-12 |